组会汇报附件.pdf

Data supplement to Guo et al. Brief cognitive–behavioural therapy for patients in the community with schizophrenia: randomised controlled trial in Beijing, China. Br J Psychiatry doi: 10.1192/bjp.bp.116.183285 Table DS1 Changes in prescribed antipsychotic drugs Assessments Brief CBT group TAU group Statistics Mean s.d. Mean s.d. t P value Chlorpromazine equivalents, mg Baseline 327.55 194.52 328.55 219.75 -0.036 0.972 12 weeks 341.17 243.13 327.22 220.20 0.437 0.663 38 weeks 336.37 168.38 333.50 229.26 0.096 0.923 64 weeks 327.50 170.72 323.07 220.44 0.155 0.877 Typical Atypical Typical Atypical χ2 P value APs, Number Baseline 21 89 21 89 0.000 1.000 12 weeks 21 82 21 87 0.029 0.864 38 weeks 18 73 18 72 0.001 0.970 64 weeks 20 74 21 75 0.010 0.920 CBT, cognitive-behavioural therapy; TAU, treatment as usual; s.d., standard deviation. APs, antipsychotic drugs. In the brief CBT group, typical APs included chlorpromazine (5 cases), perphenazine (6 cases), sulpiride (6 cases), haloperidol (3 cases), penfluridol (1 case) and atypical